Difference between revisions of "Entospletinib (GS-9973)"
Jump to navigation
Jump to search
m |
m |
||
Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
− | ===[[ | + | ===[[Chronic lymphocytic leukemia]]=== |
# Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. [http://www.bloodjournal.org/content/125/15/2336.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/25696919 PubMed] | # Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. [http://www.bloodjournal.org/content/125/15/2336.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/25696919 PubMed] | ||
Line 13: | Line 13: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
− | |||
[[Category:SYK inhibitors]] | [[Category:SYK inhibitors]] | ||
+ | [[Category:Chronic lymphocytic leukemia medications (investigational)]] | ||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] |
Revision as of 00:25, 30 April 2022
Mechanism of action
Spleen tyrosine kinase (SYK) inhibitor
Preliminary data
Chronic lymphocytic leukemia
- Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. link to original article PubMed
Also known as
- Code name: GS-9973